


CLAIMS

1- Association of compound (A) of formula (I), optionally in the form of an optical isomer, or one of its pharmaceutically acceptable salts, and clopidogrel or one of its pharmaceutically acceptable salts :



5

2- Association according to claim 1, characterised in that compound (A) is in the form of the optical isomer of (R) configuration.

3- Association according to either claim 1 or claim 2, characterised in that compound (A) is in the form of the sodium salt.

10 4- Association according to any one of claims 1, 2 or 3, characterised in that clopidogrel is in the form of the hydrogen sulphate.

15 5- Pharmaceutical composition comprising as active ingredients an association of compound (A), optionally in the form of an optical isomer, or one of its pharmaceutically acceptable salts, and clopidogrel or one of its pharmaceutically acceptable salts, in combination with one or more pharmaceutically acceptable, inert excipients or carriers.

6- Pharmaceutical composition according to claim 5, characterised in that compound (A) is in the form of the optical isomer of (R) configuration.

7- Pharmaceutical composition according to either claim 5 or claim 6, characterised in that compound (A) is in the form of the sodium salt.

8- Pharmaceutical composition according to any one of claims 5, 6 or 7, characterised in that clopidogrel is in the form of the hydrogen sulphate.

9- Pharmaceutical composition according to any one of claims 5 to 8, characterised in that the amounts of active ingredients are in the respective ranges of from 1 to 300 mg for compound (A) and from 10 to 600 mg for clopidogrel.

10- Pharmaceutical composition according to any one of claims 5 to 9, for use in the treatment of cardiovascular illnesses involving the activation of TP receptors and also in the treatment of the consequences of those illnesses.

11- Pharmaceutical composition according to claim 10, for use in the treatment of acute coronary syndrome, stable or unstable angina, endothelial dysfunction, vascular illnesses associated with atherosclerosis, hypertension, diabetes and heart failure, and in the prevention and treatment of disorders of the vascular, cardiovascular or neurovascular system and of thrombo-embolic disorders associated especially with atherosclerosis, auricular fibrillation and invasive surgical procedures in cardiology, neurology, vascular pathology and radiology.